4.2 Article

Characterization of host immunity to cytomegalovirus pp150 (UL32)

Journal

HUMAN IMMUNOLOGY
Volume 66, Issue 2, Pages 116-126

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/j.humimm.2004.10.008

Keywords

CMV; pp150; epitope mapping; recombinant MVA

Categories

Funding

  1. NCI NIH HHS [CA33572, R01-CA77544, P01-CA30206] Funding Source: Medline
  2. NCRR NIH HHS [M01-RR0043-38] Funding Source: Medline
  3. NIAID NIH HHS [AI52065] Funding Source: Medline

Ask authors/readers for more resources

The basic phosphoprotein 150 (pp150), the product of UL32 (unique long domain 32) gene of human cytomegalovirus (CMV), is an abundant component of the viral tegument and a target of human leukocyte antigen (HLA)-restricted cytotoxic T cells (CTLs) after infection. Identification of minimal cytotoxic epitopes (MCEs) from this CMV protein is of importance for peptide-based vaccines and immunotherapeutic approaches. Several pp150-specific CTL clones were derived from peripheral blood mononuclear cells of healthy CMV-positive donors with autologous fibroblasts infected either with CMV AD169 or with a recombinant vaccinia virus expressing full-length pp150 protein. HLA A*0301- and HLA A*6801-restricted CD8(+) pp150 T-cell clones derived from different donors were found to efficiently kill autologous CMV-infected fibroblasts. Fine mapping of each MCE first used a T-cell epitope prediction algorithm. Overlapping peptides within the recognized regions were screened. The analysis identified pp150(792-802) and pp150(945-955) as MCEs for the HLA A*6801 and the HLA A*0301 pp150 clones, respectively. In vitro stimulation by recombinant modified vaccinia Ankara virus expressing full-length pp150 elicited high frequencies of CMV-CTL and interferon gamma production specific for the MCE identified in all subjects. The consistent presence of pp150 T cells in CMV-exposed individuals Supports a role for this antigen in shaping the antiviral CTL response and indicates that pp150 could be a pivotal constituent of prophylactic and therapeutic CMV vaccines. (C) American Society for Histocompatibility and Immunogenetics, 2005. Published by Elsevier Inc.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.2
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available